Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | CES2 | O00748 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.49 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30112938 | 0.85 | KMT2A (0.62) | KMT2AMEN1GAACES2HTT | |
| SCHEMBL7797181 | 0.85 | KMT2A (0.62) | KMT2AMEN1GAACES2HTT | |
| SCHEMBL15295774 | 0.85 | KMT2A (0.62) | KMT2AMEN1GAACES2HTT | |
| SCHEMBL3628848 | 0.85 | KMT2A (0.62) | KMT2AMEN1GAACES2HTT | |
| SCHEMBL7255042 | 0.84 | KMT2A (0.60) | KMT2AMEN1GAACES2HTT | |
| SCHEMBL7255041 | 0.84 | KMT2A (0.60) | KMT2AMEN1GAACES2HTT | |
| SCHEMBL22952488 | 0.82 | KMT2A (0.59) | KMT2AMEN1GAACES2HTT | |
| SCHEMBL6819302 | 0.81 | KMT2A (0.57) | KMT2AMEN1GAACES2HTT | |
| SCHEMBL6819739 | 0.81 | KMT2A (0.57) | KMT2AMEN1GAACES2HTT | |
| SCHEMBL29778306 | 0.81 | KMT2A (0.57) | KMT2AMEN1GAACES2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649204-B2 | Process for the preparation of trifloxystrobin | HIKAL LIMITED (IN) | 2023-05-16 | — | — | US | disclosed |
| EP-3040073-B1 | APPLICATIONS OF SUBSTITUENT BENZYLOXY GROUP CONTAINING ETHER COMPOUNDS FOR PREPARING ANTITUMOR DRUGS | SINOCHEM CORP (CN) | 2020-07-08 | — | — | EP | disclosed |
| US-9895346-B2 | Applications of substituent benzyloxy group containing ether compounds for preparing antitumor drugs | SINOCHEM CORPORATION (CN) | 2018-02-20 | — | — | US | disclosed |
| US-20170296508-A1 | Applications of Substituent Benzyloxy Group Containing Ether Compounds for Preparing Antitumor Drugs | SHENYANG RESEARCH INSTITUTE OF CHEMICAL INDUSTRY CO., LTD. (CN) | 2017-10-19 | — | — | US | disclosed |
| EP-3040073-A1 | APPLICATIONS OF SUBSTITUENT BENZYLOXY GROUP CONTAINING ETHER COMPOUNDS FOR PREPARING ANTITUMOR DRUGS | Sinochem Corporation (CN) | 2016-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649204-B2 | Process for the preparation of trifloxystrobin | CYP3A7, CYP51A1, TREH | KMT2A 4049/4885MEN1 3130/4885GAA 22/4885 |
| US-20170296508-A1 | Applications of Substituent Benzyloxy Group Containing Ether Compounds for Preparing Antitumor Drugs | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, TPD52L2 | KMT2A 1368/4885MEN1 1507/4885GAA 4031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.